Jazz succeeds in 2 late-stage sleep apnea studies
Jazz Pharmaceuticals (JAZZ +6.1%) perks up on increased volume in response to its announcement of positive results from two Phase 3 trials assessing Orphan Drug-tagged JZP-110, a selective dopamine and norepinephrine reuptake inhibitor, for the treatment of excessive sleepiness in adults with obstructive sleep apnea (OSA).
Both studies, TONES 3 and TONES 4, met their co-primary endpoints.
Results from TONES 2, assessing JZP-110 for the treatment of excessive sleepiness associated with narcolepsy, should be available next quarter. An NDA is on tap for Q4.